Wellesley Pharmaceuticals ~ $1M Raise
At the tTAp Wellesley revised their message and strategy to reach investors. Strengthening the delivery of their clinical potential of their compound combination, Wellesley partnered with a number of catalysts who help them connect with potential partners in Europe and the US. See Wellesley in action at the tTAp
Developing a novel patented combination of existing active ingredients to treat Nocturia-the frequent need to urinate at night.
- Technology Presenter: David Dill, CEO and Founder
- Accelerator-Commercial Catalyst: Mary Osbakken, Osbakken Consulting -and- Andrew Savadelis